Overview

Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

This study evaluates the safety, tolerability, preliminary efficacy and pharmacokinetics of Simmitecan in patients with advanced solid tumors and Simmitecan, 5-fluorouracil and Leucovorin Calcium,thalidomide in patients with advanced solid tumor or advanced/metastatic colorectal cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Haihe Biopharma Co., Ltd.
ShangHai HaiHe Pharmaceutical

Collaborator:

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Treatments:

Calcium
Calcium, Dietary
Fluorouracil
Leucovorin
Levoleucovorin
Thalidomide